Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Patent metadata

Field	Value
Publication number	US-12296002-B2
Application number	US-202117351363-A
Country	US
Kind code	B2
Filing date	Jun 18, 2021
Priority date	Mar 1, 2020
Publication date	May 13, 2025
Grant date	May 13, 2025

Abstract

The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

First claim

What is claimed is:

1. An immunogenic composition against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising an antigenic recombinant protein and an adjuvant consisting of aluminum hydroxide and an unmethylated cytosine-phosphate-guanosine (CpG) motif consisting of a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 and a C-terminal T4 fibritin trimerization domain consisting of an amino acid sequence of SEQ ID NO: 2.

2. The immunogenic composition of claim 1 , wherein the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 comprise an amino acid sequence of SEQ ID NO: 1 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 1.

3. The immunogenic composition of claim 1 , wherein the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.

4. The immunogenic composition of claim 1 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 μg Al 3+ , or about 375 μg Al 3+ .

5. The immunogenic composition of claim 1 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 μg of the synthetic oligodeoxynucleotide, or wherein the immunogenic composition comprises about 750 μg, about 1500 μg, or about 3000 μg of the synthetic oligodeoxynucleotide.

6. A method for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject an effective amount of an immunogenic composition comprising an antigenic recombinant protein and an adjuvant consisting of aluminum hydroxide and an unmethylated cytosine-phosphate-guanosine (CpG) motif consisting of a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 and a C-terminal T4 fibritin trimerization domain consisting of an amino acid sequence of SEQ ID NO: 2.

7. The method of claim 6 , wherein the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 comprise an amino acid sequence of SEQ ID NO: 1 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 1.

8. The method of claim 6 , wherein the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95% 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.

9. The method of claim 6 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 μg Al 3+ , or about 375 μg Al 3+ .

10. The method of claim 6 , wherein a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 μg of the synthetic oligodeoxynucleotide, or wherein the immunogenic composition comprises about 750 μg, about 1500 μg, or about 3000 μg of the synthetic oligodeoxynucleotide.

11. The method of claim 6 , wherein the immune response comprises production of neutralizing antibodies against SARS-CoV-2 and Th1-skewed immune response.

12. The method of claim 6 , wherein the immunogenic composition is administered by intramuscular injection.

13. A method for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or preventing the subject in need thereof from contracting COVID-19 disease, comprising administering to the subject an effective amount of the immunogenic composition of claim 1 .

14. The method of claim 13 , wherein the immunogenic composition is administered by intramuscular injection.

Assignees

• Medigen Vaccine Biologics Corp
• Dynavax Tech Corp

Inventors

• Kuo Tsun-Yung
• Chen Charles
• Wu Chung-Chin
• Lin Yi-Jiun
• Lin Meei-Yun
• Wu Yu-Chi
• Campbell John Darren
• Janssen Robert S
• Novack David
• Coffman Robert
• Traquina Paula

Classifications

• C12N2795/10071

  Demonstrated in vivo effect · CPC title

• C12N2795/10022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2770/20071

  Demonstrated in vivo effect · CPC title

• C12N2770/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title